{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:02Z","timestamp":1786982762304,"version":"build-2736575974"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s40262-018-0710-1","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T22:11:35Z","timestamp":1537999895000},"page":"565-592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cardiovascular Risk Management and Hepatitis C: Combining Drugs"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-9758","authenticated-orcid":false,"given":"Elise J.","family":"Smolders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-5907","authenticated-orcid":false,"given":"Peter J. G.","family":"ter Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"issue":"4","key":"710_CR1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","volume":"58","author":"D Burger","year":"2013","unstructured":"Burger D, Back D, Buggisch P, Buti M, Craxi A, Foster G, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58(4):792\u2013800.","journal-title":"J Hepatol"},{"issue":"5","key":"710_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/COH.0000000000000185","volume":"10","author":"O El-Sherif","year":"2015","unstructured":"El-Sherif O, Khoo S, Solas C. Key drug\u2013drug interactions with direct-acting antiviral in HIV-HCV coinfection. Curr Opin HIV AIDS. 2015;10(5):348\u201354.","journal-title":"Curr Opin HIV AIDS"},{"issue":"10","key":"710_CR3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","volume":"10","author":"JJ Kiser","year":"2013","unstructured":"Kiser JJ, Burton JR Jr, Everson GT. Drug\u2013drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10(10):596\u2013606.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"26","key":"710_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/MEG.0000000000000152","volume":"2014","author":"JC Lauffenburger","year":"2014","unstructured":"Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KLR, Fried MW, Farley JF. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol. 2014;2014(26):1073\u201382.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"710_CR5","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/apt.13769","volume":"44","author":"J Vermehren","year":"2016","unstructured":"Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44(8):856\u201365.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"710_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/QAI.0000000000001488","volume":"76","author":"EJ Smolders","year":"2017","unstructured":"Smolders EJ, Smit C, De Kanter CT, Dofferiiof ASM, Arends JE, Brinkman K, et al. Brief report: high need to switch cART or comedication with the initiation of DAAs in elderly HIV\/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2017;76(2):193\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"710_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/hiv.12570","volume":"19","author":"EJ Smolders","year":"2018","unstructured":"Smolders EJ, Smit C, de Kanter C, Dofferhoff A, Arends JE, Brinkman K, et al. Management of drug interactions with direct-acting antivirals in Dutch HIV\/hepatitis C virus-coinfected patients: adequate but not perfect. HIV Med. 2018;19(3):216\u201326.","journal-title":"HIV Med"},{"issue":"5","key":"710_CR8","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/2050640616678151","volume":"5","author":"EJ Smolders","year":"2017","unstructured":"Smolders EJ, Berden FA, de Kanter CT, Kievit W, Drenth JP, Burger DM. The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug\u2013drug interactions. United Eur Gastroenterol J. 2017;5(5):648\u201357.","journal-title":"United Eur Gastroenterol J"},{"issue":"1 Suppl","key":"710_CR9","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","volume":"61","author":"F Negro","year":"2014","unstructured":"Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1 Suppl):S69\u201378.","journal-title":"J Hepatol"},{"issue":"6","key":"710_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3109\/00365521.2015.1021709","volume":"50","author":"S M\u00f8ller","year":"2015","unstructured":"M\u00f8ller S, Bendtsen F. Complications of cirrhosis. A 50\u00a0years flashback. Scand J Gastroenterol. 2015;50(6):763\u201380.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"710_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/jcpt.12403","volume":"41","author":"A Lorenzo-Pinto de","year":"2016","unstructured":"de Lorenzo-Pinto A, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Ahumada-Jimenez A, Herranz-Alonso A, Marzal-Alfaro MB, et al. Decreased INR after acenocoumarol, ombitasvir\/paritaprevir\/ritonavir and dasabuvir co-administration. J Clin Pharm Ther. 2016;41(4):444\u20136.","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"710_CR12","doi-asserted-by":"publisher","first-page":"1378.e1","DOI":"10.1053\/j.gastro.2015.07.051","volume":"149","author":"S Renet","year":"2015","unstructured":"Renet S, Chaumais MC, Antonini T, Zhao A, Thomas L, Savoure A, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149(6):1378.e1\u20131380.e1.","journal-title":"Gastroenterology"},{"issue":"19","key":"710_CR13","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMc1505967","volume":"373","author":"H Fontaine","year":"2015","unstructured":"Fontaine H, Lazarus A, Pol S, Pecriaux C, Bagate F, Sultanik P, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373(19):1886\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"710_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/clpt.2013.86","volume":"94","author":"KM Giacomini","year":"2013","unstructured":"Giacomini KM, Huang SM. Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther. 2013;94(1):3\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"710_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2217\/pgs-2017-0194","volume":"18","author":"MA Bahar","year":"2017","unstructured":"Bahar MA, Setiawan D, Hak E, Wilffert B. Pharmacogenetics of drug\u2013drug interaction and drug\u2013drug\u2013gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics. 2017;18(7):701\u201339.","journal-title":"Pharmacogenomics"},{"key":"710_CR16","unstructured":"FDA. Coreg: prescribing information. \n                    https:\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB01136.pdf?1265922801\n                    \n                  . Accessed 6 Mar 2018."},{"issue":"6","key":"710_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.dld.2017.01.144","volume":"49","author":"L Boglione","year":"2017","unstructured":"Boglione L, De Nicolo A, Mornese Pinna S, Cusato J, Favata F, Ariaudo A, et al. Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations. Dig Liver Dis. 2017;49(6):705\u20138.","journal-title":"Dig Liver Dis"},{"key":"710_CR18","unstructured":"EMA. Sovaldi: summary of product characteristics. 2014. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002798\/WC500160597.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR19","unstructured":"FDA. Sovaldi: prescribing information. 2014. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204671s001lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"issue":"1","key":"710_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40268-017-0222-8","volume":"18","author":"T Garimella","year":"2018","unstructured":"Garimella T, Tao X, Sims K, Chang Y-T, Rana J, Myers E, et al. Effects of a fixed-dose co-formulation of daclatasvir, asunaprevir, and beclabuvir on the pharmacokinetics of a cocktail of cytochrome P450 and drug transporter substrates in healthy subjects. Drugs R&D. 2018;18(1):55\u201365.","journal-title":"Drugs R&D"},{"key":"710_CR21","unstructured":"EMA. Daklinza: summary of product characteristics. 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003768\/WC500172848.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR22","unstructured":"FDA. Daklinza: prescribing information. 2015. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206843Orig1s000lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR23","unstructured":"EMA. Viekirax: summary of product characteristics. 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003839\/WC500183997.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR24","unstructured":"FDA. Viekira Pak: prescribing information. 2014. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206619lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"issue":"3","key":"710_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1067\/mcp.2003.28","volume":"73","author":"MH Skinner","year":"2003","unstructured":"Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73(3):170\u20137.","journal-title":"Clin Pharmacol Ther."},{"key":"710_CR26","unstructured":"EMA. Norvir: summary of product characteristics. 2014. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000127\/WC500028728.pdf\n                    \n                  . Accessed 30 Jun 2016."},{"issue":"1","key":"710_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1124\/jpet.106.103390","volume":"318","author":"L Liu","year":"2006","unstructured":"Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, et al. Vectorial transport of enalapril by Oatp1a1\/Mrp2 and OATP1B1 and OATP1B3\/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006;318(1):395\u2013402.","journal-title":"J Pharmacol Exp Ther"},{"key":"710_CR28","unstructured":"EMA. Maviret: summary of product characteristics. 2017. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004430\/WC500233677.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR29","unstructured":"FDA. Mavyret: prescribing information. 2017. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209394s000lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"issue":"8","key":"710_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/bdd.1961","volume":"36","author":"H Chapy","year":"2015","unstructured":"Chapy H, Klieber S, Brun P, Gerbal-Chaloin S, Boulenc X, Nicolas O. PBPK modeling of irbesartan: incorporation of hepatic uptake. Biopharm Drug Dispos. 2015;36(8):491\u2013506.","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"710_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1124\/dmd.105.009175","volume":"34","author":"N Ishiguro","year":"2006","unstructured":"Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006;34(7):1109\u201315.","journal-title":"Drug Metab Dispos"},{"key":"710_CR32","unstructured":"FDA. Hyzaar: prescribing information. 2011. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020387s052lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"issue":"2","key":"710_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/0091270010365717","volume":"51","author":"S Rebello","year":"2011","unstructured":"Rebello S, Leon S, Hariry S, Dahlke M, Jarugula V. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants. J Clin Pharmacol. 2011;51(2):218\u201328.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"710_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/0091270010365885","volume":"51","author":"T Tapaninen","year":"2011","unstructured":"Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol. 2011;51(3):359\u201367.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"710_CR35","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1177\/0091270010385934","volume":"51","author":"S Rebello","year":"2011","unstructured":"Rebello S, Compain S, Feng A, Hariry S, Dieterich HA, Jarugula V. Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects. J Clin Pharmacol. 2011;51(11):1549\u201360.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"710_CR36","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/0091270008323258","volume":"48","author":"S Vaidyanathan","year":"2008","unstructured":"Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48(11):1323\u201338.","journal-title":"J Clin Pharmacol"},{"key":"710_CR37","unstructured":"EMA. Exviera: summary of product characteristics. 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003837\/WC500182233.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR38","unstructured":"FDA. Inspra: prescribing information. 2002. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021437s013lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR39","unstructured":"FDA. Verelan: prescribing information. 2014. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019614s050lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR40","unstructured":"EMA. Olysio: summary of product characteristics. 2014. \n                    http:\/\/ec.europa.eu\/health\/documents\/community-register\/2014\/20140514128513\/anx_128513_en.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR41","unstructured":"EMA. Zepatier: summary of product characteristics. 2016. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004126\/WC500211235.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR42","unstructured":"FDA. Zepatier: prescribing information. 2016. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208261Orig1s000lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"issue":"4","key":"710_CR43","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1665-2681(19)30853-1","volume":"13","author":"CT Kanter","year":"2014","unstructured":"Kanter CT, Luin M, Solas C, Burger DM, Vrolijk JM. Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin. Ann Hepatol. 2014;13(4):452\u20135.","journal-title":"Ann Hepatol"},{"issue":"8","key":"710_CR44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/ajhp\/59.8.728","volume":"59","author":"CH Cheng","year":"2002","unstructured":"Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm. 2002;59(8):728\u201330.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"710_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/108729100318091","volume":"14","author":"DM Aboulafia","year":"2000","unstructured":"Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDS. 2000;14(1):13\u20138.","journal-title":"AIDS Patient Care STDS"},{"issue":"4","key":"710_CR46","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3122\/jabfm.2007.04.060187","volume":"20","author":"GA Schmidt","year":"2007","unstructured":"Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med. 2007;20(4):411\u20136.","journal-title":"J Am Board Fam Med"},{"key":"710_CR47","unstructured":"Martin CM, Hoffman V, Berggren RE. Rhabdomyolysis in a patient receiving simvastatin concurrently with highly active antriretroviral therapy [abstract no. 1297]. 40th ICAAC; 17\u201320 2000; Toronto."},{"issue":"5","key":"710_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/108729103321655854","volume":"17","author":"JB Mah Ming","year":"2003","unstructured":"Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir\/ritonavir in a patient with HIV. AIDS Patient Care STDS. 2003;17(5):207\u201310.","journal-title":"AIDS Patient Care STDS"},{"issue":"10","key":"710_CR49","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1086\/344179","volume":"35","author":"CB Hare","year":"2002","unstructured":"Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin\u2013nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35(10):e111\u20132.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"710_CR50","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0002-9343(01)01135-4","volume":"112","author":"JG Castro","year":"2002","unstructured":"Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med. 2002;112(6):505.","journal-title":"Am J Med"},{"issue":"2","key":"710_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/QAI.0b013e3181b0610e","volume":"52","author":"KH Busse","year":"2009","unstructured":"Busse KH, Hadigan C, Chairez C, Alfaro RM, Formentini E, Kovacs JA, et al. Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. J Acquir Immune Defic Syndr. 2009;52(2):235\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"710_CR52","unstructured":"EMA. Plavix: summary of product characteristics. 2008. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000174\/WC500042189.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR53","unstructured":"FDA. Plavix: prescribing information. 2009. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020839s044lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR54","unstructured":"FDA. Effient: prescribing information. 2009. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022307s002lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR55","unstructured":"EMA. Efient: summary of product characteristics. 2009. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000984\/WC500021971.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR56","unstructured":"EMA. Brilique: summary of product characteristics. 2010. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001241\/WC500100494.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"issue":"5","key":"710_CR57","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","volume":"81","author":"NA Farid","year":"2007","unstructured":"Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81(5):735\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"710_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0637-6","author":"N Marsousi","year":"2018","unstructured":"Marsousi N, Daali Y, Fontana P, Reny JL, Ancrenaz-Sirot V, Calmy A, et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin Pharmacokinet. 2018. \n                    https:\/\/doi.org\/10.1007\/s40262-018-0637-6\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"710_CR59","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/21556660.2013.785413","volume":"2","author":"R Teng","year":"2013","unstructured":"Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2013;2(1):30\u20139.","journal-title":"J Drug Assess"},{"issue":"3","key":"710_CR60","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/cpt.407","volume":"100","author":"N Marsousi","year":"2016","unstructured":"Marsousi N, Samer CF, Fontana P, Reny JL, Rudaz S, Desmeules JA, et al. Coadministration of ticagrelor and ritonavir: toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin Pharmacol Ther. 2016;100(3):295\u2013304.","journal-title":"Clin Pharmacol Ther"},{"key":"710_CR61","unstructured":"EMA. Vosevi: summary of product characteristics. 2017. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004350\/WC500235373.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR62","unstructured":"FDA. Vosevi: prescribing information. 2017. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209195s000lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR63","unstructured":"EMA. Lixiana: summary of product characteristics. 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002629\/WC500189045.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR64","unstructured":"EMA. Eliquis: summary of product characteristics. 2011. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR65","unstructured":"FDA. Eliquis: prescribing information. 2012. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202155s012lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"issue":"5","key":"710_CR66","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/hep.28752","volume":"64","author":"CP Regan","year":"2016","unstructured":"Regan CP, Morissette P, Regan HK, Travis JJ, Gerenser P, Wen J, et al. Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys. Hepatology. 2016;64(5):1430\u201341.","journal-title":"Hepatology"},{"key":"710_CR67","unstructured":"Important drug warning. Serious and life-threatening cases of symptomatic bradycardia as well as one case of fatal cardiac arrest reported with coadministration of amiodarone with either Harvoni\u00ae (ledipasvir and sofosbuvir fixed-dose combination) or with Sovaldi\u00ae (sofosbuvir) in combination with another direct acting antiviral. Dear Healthcare Provider letter: Gilead Sciences, 20 March 2015. 2015. \n                    http:\/\/www.natap.org\/2015\/HCV\/SVD20March15FINAL-1.pdf"},{"key":"710_CR68","unstructured":"FDA. FDA warns of serious slowing of the heart rate when the antiarrhythmic drug amiodarone us used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug. \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm439484.htm\n                    \n                  . Accessed 17 May 2015."},{"issue":"6","key":"710_CR69","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1053\/j.gastro.2015.09.031","volume":"149","author":"DJ Back","year":"2015","unstructured":"Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology. 2015;149(6):1315\u20137.","journal-title":"Gastroenterology"},{"issue":"308","key":"710_CR70","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.taap.2016.08.006","volume":"1","author":"A Lagrutta","year":"2016","unstructured":"Lagrutta A, Zeng H, Imredy J, Balasubramanian B, Dech S, Lis E, et al. Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells. Toxicol Appl Pharmacol. 2016;1(308):66\u201376.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"710_CR71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40264-017-0586-2","volume":"41","author":"D Caldeira","year":"2018","unstructured":"Caldeira D, Rodrigues FB, Duarte MM, Sterrantino C, Barra M, Goncalves N, et al. Cardiac harms of sofosbuvir: systematic review and meta-analysis. Drug Saf. 2018;41(1):77\u201386.","journal-title":"Drug Saf"},{"issue":"2","key":"710_CR72","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/dmd.114.059311","volume":"43","author":"Y Chen","year":"2015","unstructured":"Chen Y, Mao J, Hop CE. Physiologically based pharmacokinetic modeling to predict drug\u2013drug interactions involving inhibitory metabolite: a case study of amiodarone. Drug Metab Dispos. 2015;43(2):182\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"710_CR73","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/toxsci\/kfw153","volume":"154","author":"DC Millard","year":"2016","unstructured":"Millard DC, Strock CJ, Carlson CB, Aoyama N, Juhasz K, Goetze TA, et al. Identification of drug\u2013drug interactions in vitro: a case study evaluating the effects of sofosbuvir and amiodarone on hiPSC-derived cardiomyocytes. Toxicol Sci. 2016;154(1):174\u201382.","journal-title":"Toxicol Sci"},{"issue":"5","key":"710_CR74","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/hep.28752","volume":"64","author":"CP Regan","year":"2016","unstructured":"Regan CP, Morissette P, Regan HK, Travis JJ, Gerenser P, Wen J, et al. Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys. Hepatology. 2016;64(5):1430\u201341.","journal-title":"Hepatology"},{"key":"710_CR75","unstructured":"EMA. Epclusa: summary of product characteristics. 2016. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004210\/WC500211151.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"issue":"6","key":"710_CR76","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/dmd.115.066845","volume":"44","author":"LM Almond","year":"2016","unstructured":"Almond LM, Mukadam S, Gardner I, Okialda K, Wong S, Hatley O, et al. Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model. Drug Metab Dispos. 2016;44(6):821\u201332.","journal-title":"Drug Metab Dispos"},{"key":"710_CR77","unstructured":"FDA. Atenolol: prescribing information. 2007. \n                    https:\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB00335.pdf?1461363666\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR78","unstructured":"FDA. Ziac: prescribing information. 2007. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020186s023lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR79","unstructured":"Dutch Medicines Evaluation Board (CBG). Labetalol ratiopharm: productinformatie. 2017. \n                    https:\/\/db.cbg-meb.nl\/IB-teksten\/h11106.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR80","unstructured":"FDA. Metoprolol extended-release tablets: prescribing information. 2007. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/019962s036lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR81","unstructured":"FDA. Byvalson: prescribing information. 2016. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/206302s000lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR82","unstructured":"FDA. Propranolol hydrochloride extended-release capsules: prescribing information. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018553s037lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR83","unstructured":"FDA. Sotalol hydrochloride injection: prescribing information. 1992. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022306s000lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR84","unstructured":"FDA. Capoten: prescribing information. 2015. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/018343s086lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR85","unstructured":"FDA. Vaseretic: prescribing information. 2011. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019221s041lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR86","unstructured":"FDA. Monopril: prescribing information. 2002. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/19915se5-037_monopril_lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR87","unstructured":"FDA. Zestorectic: prescribing information. 2012. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019888s052lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR88","unstructured":"FDA. Aceon: prescribing information. 2012. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020184s019lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR89","unstructured":"FDA. Accuretic: prescribing information. 2013. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020125s015lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR90","unstructured":"FDA. Altace: prescribing information. 2013. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019901s060lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR91","unstructured":"FDA. Atacand: prescribing information. 2015. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021093s019lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR92","unstructured":"FDA. Avalide: prescribing information. 1997. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020758s070lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR93","unstructured":"EMA. Irbesartan teva: summary of producht characteristics. 2009. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001093\/WC500036105.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR94","unstructured":"FDA. Benicar HCT: prescribing information. 2006. \n                    https:\/\/www.uptodate.com\/contents\/olmesartan-drug-information?source=preview&search=olmesartan&anchor=F9837691#F9837691\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR95","unstructured":"FDA. Micardis HCT: prescribing information. 2014. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021162s037lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR96","unstructured":"FDA. Exforge: prescribing information. 2007. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021990s017lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR97","unstructured":"FDA. Tekamlo: prescribing information. 2010. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022545s017lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR98","unstructured":"Dutch Medicines Evaluation Board (CBG). Amiloride: summary of product characteristics. 2013. \n                    https:\/\/db.cbg-meb.nl\/IB-teksten\/h11128.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR99","unstructured":"FDA. Bumex: prescribing information. 2017. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018225s026lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR100","unstructured":"FDA. Diuril: prescribing information. 2008. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/011870s040lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR101","unstructured":"FDA. Furosemide tablets USP: prescribing information. 2017. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018823s044lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR102","unstructured":"FDA. Lozol: prescribing information. 2005. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/018538s028lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR103","unstructured":"FDA. Carospir: prescribing information. 1960. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209478s000lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR104","unstructured":"FDA. Maxzide: prescribing information. 2011. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019129s043lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR105","unstructured":"FDA. Lotrel: prescribing information. 1995. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020364s065lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR106","unstructured":"Dutch Medicines Evaluation Board (CBG). Cyress: summary of product characteristics. 2013. \n                    https:\/\/db.cbg-meb.nl\/IB-teksten\/h20554.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR107","unstructured":"FDA. Cardizem LA: prescribing information. 1982. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021392s019lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR108","unstructured":"FDA. Plendil: prescribing information. 2012. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019834s025lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR109","unstructured":"Dutch Medicines Evaluation Board (CBG). Lercanidipine HCL: product information. 2015. \n                    https:\/\/db.cbg-meb.nl\/IB-teksten\/h103614.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR110","unstructured":"FDA. Nicardipine hydrochloride: prescribing information. 1988. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/022276s011lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR111","unstructured":"FDA. Procardia XL: prescribing information. 2013. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019684s026lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR112","unstructured":"FDA. Liptruzet: prescribing information. 2013. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/200153s006lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR113","unstructured":"FDA. Vytorin: prescribing information. 2004. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021687s036lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR114","unstructured":"FDA. Altoprev: prescribing information. 2002. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021316s031lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR115","unstructured":"FDA. Pravachol: prescribing information. 1991. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019898s061lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR116","unstructured":"FDA. Crestor: prescribing information. 2003. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021366s032lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR117","unstructured":"Dutch Medicines Evaluation Board (CBG). Bezalip: summary of product characteristics. 2015. \n                    https:\/\/db.cbg-meb.nl\/IB-teksten\/h15982.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR118","unstructured":"Dutch Medicines Evaluation Board (CBG). Ciprofibraat Amdipharm: summary of product characteristics. 2016. \n                    https:\/\/db.cbg-meb.nl\/IB-teksten\/h111600.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR119","unstructured":"FDA. Antara: prescribing information. 1993. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021695s012lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR120","unstructured":"FDA. Lopid: prescription information. 2016. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/018422s055lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR121","unstructured":"FDA. Durlaza: prescribing information. 2015. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/200671s000lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR122","unstructured":"FDA. Aggrenox: prescribing information. 1999. \n                    http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Aggrenox%20Caps\/Aggrenox.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR123","unstructured":"Dutch Medicines Evaluation Board (CBG). Ascal 38 Brisper: summary of product characteristics. 2014. \n                    https:\/\/db.cbg-meb.nl\/IB-teksten\/h21994.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR124","unstructured":"FDA. Brilinta: prescribing information. 2011. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/022433s020lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR125","unstructured":"Dutch Medicines Evaluation Board (CBG). Acenocoumarol CF: summary of product characteristics. 2017. \n                    https:\/\/db.cbg-meb.nl\/IB-teksten\/h50674.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR126","unstructured":"Dutch Medicines Evaluation Board (CBG). Fenprocoumon Sandoz: summary of product characteristics. 2017. \n                    https:\/\/db.cbg-meb.nl\/IB-teksten\/h21068.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR127","unstructured":"FDA. Coumadin: prescribing information. 1954. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/009218s017lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR128","unstructured":"FDA. Fragmin: prescribing information. 1994. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020287s069lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR129","unstructured":"FDA. Lovenox: prescribing information. 1993. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020164s102lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR130","unstructured":"FDA. Heparin sodium: prescribing information. 2008. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/017029s108lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR131","unstructured":"Dutch Medicines Evaluation Board (CBG). Fraxiparine: summary of product characteristics. 2017. \n                    https:\/\/db.cbg-meb.nl\/IB-teksten\/h11876.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR132","unstructured":"FDA. Arixtra: product information. 2001. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021345s035lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR133","unstructured":"EMA. Pradaxa: summary of product characteristics. 2013. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR134","unstructured":"FDA. Pradaxa: prescribing information. 2010. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022512s007lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR135","unstructured":"FDA. Savaysa: prescribing information. 2015. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf\n                    \n                  . Accessed 6 Mar 2018."},{"key":"710_CR136","unstructured":"EMA. Xarelto: summary of product characteristics. 2013. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf\n                    \n                  . Accessed 8 Mar 2018."},{"key":"710_CR137","unstructured":"FDA. Xarelto: prescribing information. 2011. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202439s001lbl.pdf\n                    \n                  . Accessed 8 Feb 2018."},{"key":"710_CR138","unstructured":"FDA. NitroMist: prescribing information. 2006. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021780s007lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR139","unstructured":"Dutch Medicines Evaluation Board (CBG). Isosorbide dinitraat retard CF: summary of product characteristics. 2010. \n                    https:\/\/db.cbg-meb.nl\/Bijsluiters\/h56834.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR140","unstructured":"FDA. Monoket: prescribing information. 2014. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020215s024lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR141","unstructured":"(NVZA) NVvZ. Therapeutic Drug Monitoring Monografie. 2018. \n                    http:\/\/tdm-monografie.org\/tdm-monografieen\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR142","unstructured":"FDA. Cordarone: prescribing information. 2015. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018972s053lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR143","unstructured":"FDA. Nexterone: prescribing information. 2008. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022325lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR144","unstructured":"FDA. Digoxin oral solution: prescribing information. 1982. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021648s008lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR145","unstructured":"EMA. Guideline on the investigation of drug interactions. 21 Jun 2012. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf\n                    \n                  . Accessed 14 Feb 2015."},{"key":"710_CR146","unstructured":"EMA. Harvoni: summary of product characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003850\/WC500177995.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR147","unstructured":"FDA. Harvoni: prescribing information. 2014. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205834s000lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR148","unstructured":"FDA. Olysio: prescribing information. 2014. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205123s002lbledt.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR149","unstructured":"FDA. Epclusa: prescribing information. 2016. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208341s000lbl.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR150","unstructured":"EMA. Sovaldi product information. 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002798\/WC500160597.pdf\n                    \n                  . Accessed 7 Mar 2018."},{"key":"710_CR151","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd705","volume":"1","author":"DM Roden","year":"2002","unstructured":"Roden DM, George AL Jr. The genetic basis of variability in drug responses. Nat Rev Drug Discov. 2002;1:37\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"710_CR152","unstructured":"Back D. Update on some key drug interaction issues. EASL 2017. EMW - Practical management of drug-drug interaction in patients treated with DAA, Friday 21 April 2017."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0710-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0710-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0710-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T20:10:46Z","timestamp":1569528646000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0710-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":152,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["710"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0710-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"27 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"EJS declares having received travels grants from Abbvie and Gilead. SW and PJGTH declare that they have no conflicts of interest that are directly relevant to the content of this review. DMB is on the advisory boards for AbbVie, BMS, Gilead, Janssen, and Merck and received sponsorship\/research grants from BMS, Gilead, Janssen, Merck, and Viiv. However, these conflicts of interest did not influence the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding was used in the preparation of this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}